The Investors Called

Discussion in 'Radius Health' started by anonymous, Mar 5, 2018 at 11:45 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    They want their money back

    Great selling: $7 M last quarter and lost $70M

    Can you dummies close?
     

  2. anonymous

    anonymous Guest

    Did you not hear Jesper and Pepe on the call? They told Wall Street we are poised for greatness! Lol
     
  3. anonymous

    anonymous Guest

    Jesper is living off his diabetes success from Nova which from what I have heard had virtually nothing to do with Jesper. Oh by the way, Tymlos not for diabetes!!!
     
  4. anonymous

    anonymous Guest

    stock trading in low 30’s, probably heading for 20’s. We can only hand the investors/share holders the “wait until next quarter” bull one more quarter. If all the formulary preference crap doesn’t produce breakthroughs soon, it’s going to get a lot worse.
     
  5. anonymous

    anonymous Guest

     
  6. anonymous

    anonymous Guest

    bwahahaha, we're not even through One Quarter Yet! and you say we can't do it for more quarters obviously you don't work in Pharma 35% Nbrx share 23% Nrx share 13% TRX share that's freaking amazing for 8 months and no coverage until January 1st what a moron you are
     
  7. anonymous

    anonymous Guest

    “Such are promises,
    All lies and jests,
    Still a man hears what he wants to hear,
    And disregards the rest”
    Simon & Garfunkel

    Keep drinking the Kool Aid and buying KC and JB’s stupidity. But keep job hunting too.
     
  8. anonymous

    anonymous Guest

    KC and JB are knights in shining armor. Born leaders breaking records in 2018.
     
  9. anonymous

    anonymous Guest

     
  10. anonymous

    anonymous Guest

    laughable. so so sad
     
  11. anonymous

    anonymous Guest

    You consider $7 million in sales amazing? RH is blowing through over $20 million a month. Investors count dollars and revenue, not massaged market share numbers.
     
  12. anonymous

    anonymous Guest

    Do you enjoy embarrassing yourself? It's called a launch yes you're going to burn through some cash: money will follow
    the market share and the market share is there and we're only a few weeks into actually having some insurance coverage. Please no one could be as dumb as you're making yourself sound
     
  13. anonymous

    anonymous Guest

    Oncology clinical trial, patch clinical trial, Europe approval, cost of 30%+ turnover rate, the fact that we had $1.05 billion in cash, but we have already spent $797 million of it. There's $253 million left to do all this with. At the rate RH is bleeding cash, that won't last. So what is the answer "Grand Wizard?" Go back and try to raise even more public capital? Know your numbers, which obviously you don't.
     
  14. anonymous

    anonymous Guest

    Above poster is spot on. This company can't be sustained long term. Best bet is Radius is sold by 2019.
     
  15. anonymous

    anonymous Guest

    Hey Geniuses the consensus is that radius will earn 79 million this year which means that by q1 next year we will be profitable and then we will have the money to do the trials that's why we scheduled them for next year, not that tough to figure out
     
  16. anonymous

    anonymous Guest

    Well well lookie what we have here a couple of Lilly reps that understand the only chance they have is if radius goes bankrupt because they sure as hell Kniw they can't sell against it
     
  17. anonymous

    anonymous Guest

    Consensus is $79 million? Is that the "Radius Consensus?" Because Radius has yet to hit a single quarterly number they have given Wall Street in the 3 quarters since launch. You may want to put down the kool-aid waterhose that the Novo and AZ rejects have been feeding you.
     
  18. anonymous

    anonymous Guest

    The company is a joke
    It will belly up before much longer
     
  19. anonymous

    anonymous Guest

    umm, ever heard of JP Morgan or Morgan Stanley, or Black Rock, its there consensus you friggin Lame Brain
     
  20. anonymous

    anonymous Guest

    Oh and by the way pathetic Lilly rep the consensus for the fourth quarter was between 5 and 7 million in income they reported 7.7 so they did beat the earnings but obviously actual facts don't matter to you